AI Summary & Key Takeaways
AI InsightConclusion: We recommend that HFpEF, which is associated with increased cardiovascular mortality and morbidity in patients with CRMD, should be screened clinically and with NT-proBNP and evaluated with transthoracic echocardiography if necessary.
📌 3 Key Takeaways
Abstract
Aim: Despite the prevalence of cardiorenal metabolic diseases (CRMD) in heart failure with preserved ejection fraction (HFpEF) patients and their significant complications, they are thought to be under-recognized and under-screened. In our study, we aimed to evaluate patients with HFpEF who were followed up in our internal medicine clinic. Methods: Our retrospective and cross-sectional study included 348 patients with HFpEF. Patients were evaluated according to laboratory, demographic, clinical, electrocardiographic and ultrasonographic findings. Results: Of the patients, 37.95% had diabetes mellitus, 23.3% had chronic kidney disease, 70.1% had hypertension and 59.2% had metabolic dysfunction-associated steatotic liver disease. The mean NT-proBNP level was 360.7 ± 13.7. Conclusion: We recommend that HFpEF, which is associated with increased cardiovascular mortality and morbidity in patients with CRMD, should be screened clinically and with NT-proBNP and evaluated with transthoracic echocardiography if necessary.